[go: up one dir, main page]

MX2017013248A - Compuesto del inhibidor fgfr4 cristalino y usos del mismo. - Google Patents

Compuesto del inhibidor fgfr4 cristalino y usos del mismo.

Info

Publication number
MX2017013248A
MX2017013248A MX2017013248A MX2017013248A MX2017013248A MX 2017013248 A MX2017013248 A MX 2017013248A MX 2017013248 A MX2017013248 A MX 2017013248A MX 2017013248 A MX2017013248 A MX 2017013248A MX 2017013248 A MX2017013248 A MX 2017013248A
Authority
MX
Mexico
Prior art keywords
crystalline
cristalino
fgfr4
inhibitor
composite
Prior art date
Application number
MX2017013248A
Other languages
English (en)
Other versions
MX390378B (es
Inventor
Sanders Kristen
Yoshida Kenshi
Chanda Arani
Moniz George
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2017013248A publication Critical patent/MX2017013248A/es
Publication of MX390378B publication Critical patent/MX390378B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se una serie de formas cristalinas de N-(2-((6-(3-(2,6-dicloro-3,5 -dimetoxifenil)-1-metilureido) pirimidin-4-il)amino)-5-(4-etilpipe razin-1-il)fenil)acrilamida. í‰stas incluyen una forma cristalina de base libre, una forma cristalina en sal monoclorhidrata, una forma cristalina de sal diclorhidrata, y una forma cristalina de sal etansulfonato. Tambión se proporcionan los métodos para elaborar y utilizar los compuestos cristalinos.
MX2017013248A 2015-04-14 2016-04-13 Compuesto del inhibidor fgfr4 cristalino y usos del mismo. MX390378B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562147313P 2015-04-14 2015-04-14
PCT/US2016/027334 WO2016168331A1 (en) 2015-04-14 2016-04-13 Crystalline fgfr4 inhibitor compound and uses thereof

Publications (2)

Publication Number Publication Date
MX2017013248A true MX2017013248A (es) 2018-07-06
MX390378B MX390378B (es) 2025-03-12

Family

ID=55806857

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013248A MX390378B (es) 2015-04-14 2016-04-13 Compuesto del inhibidor fgfr4 cristalino y usos del mismo.

Country Status (13)

Country Link
US (2) US10562888B2 (es)
EP (1) EP3283465B1 (es)
JP (3) JP6431622B2 (es)
KR (1) KR102548229B1 (es)
CN (1) CN107660200B (es)
AU (2) AU2016248056B2 (es)
CA (1) CA2982562C (es)
ES (1) ES2864712T3 (es)
IL (1) IL254974B (es)
MX (1) MX390378B (es)
RU (1) RU2763328C2 (es)
SG (2) SG10201810057UA (es)
WO (1) WO2016168331A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201810057UA (en) * 2015-04-14 2018-12-28 Eisai R&D Man Co Ltd Crystalline fgfr4 inhibitor compound and uses thereof
US11357769B2 (en) 2016-05-10 2022-06-14 Eisai R&D Management Co., Ltd. Drug combinations for reducing cell viability and/or cell proliferation
AU2017315357B2 (en) * 2016-08-23 2022-12-01 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of hepatocellular carcinoma
US11008292B2 (en) * 2016-11-17 2021-05-18 Guangdong Zhongsheng Pharmaceutical Co., Ltd FGFR4 inhibitor and preparation method and use thereof
CN109422760B (zh) * 2017-09-01 2022-05-27 南京圣和药物研发有限公司 Fgfr4抑制剂及其应用
CA3088292A1 (en) 2018-01-10 2019-07-18 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of hepatocellular carcinoma
EP4045484A4 (en) * 2019-10-14 2023-09-06 Hutchison Medipharma Limited SALTS OF A COMPOUND AND CRYSTALLINE FORMS THEREOF
WO2021230886A1 (en) 2020-05-15 2021-11-18 Eisai R&D Management Co., Ltd. A method for treating cancer with an oral dosage form of an fgfr4 inhibitor
US20230172867A1 (en) * 2020-05-15 2023-06-08 Eisai R&D Management Co., Ltd. A method for treating cancer with an oral dosage form of an fgfr4 inhibitor
CN116947825B (zh) * 2022-04-14 2025-11-28 浙江海正药业股份有限公司 Fgfr4选择性抑制剂化合物的晶型及其制备方法和用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE190978T1 (de) * 1994-11-14 2000-04-15 Warner Lambert Co 6-aryl-pyrido(2,3-d)pyrimidine und -naphthyridine zur hemmung der durch protein-tyrosin-kinase hervorgerufenen zellvermehrung
KR20010043829A (ko) 1998-05-26 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 비시클릭 피리미딘 및 비시클릭3,4-디히드로피리미딘
BRPI0413005A (pt) 2003-07-29 2006-09-26 Irm Llc compostos e composições como inibidores da proteìna cinase
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
WO2006038112A1 (en) 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
WO2007071752A2 (en) 2005-12-21 2007-06-28 Novartis Ag Pyrimidinyl aryl urea derivatives being fgf inhibitors
EP1918376A1 (en) 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
US20090062320A1 (en) 2007-08-28 2009-03-05 Vito Guagnano Method of Treating Disorders Mediated by the Fibroblast Growth Factor Receptor
BRPI0914682B8 (pt) 2008-06-27 2021-05-25 Avila Therapeutics Inc compostos de heteroarila e composições compreendendo os referidos compostos
AR079257A1 (es) 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
CA2786276A1 (en) 2010-01-14 2011-07-21 Yale University Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
WO2012136732A1 (en) 2011-04-08 2012-10-11 Ab Science Treatment of multiple myeloma with masitinib
CN102816162B (zh) 2011-06-10 2016-04-27 中国科学院广州生物医药与健康研究院 嘧啶并嘧啶酮类化合物及其药用组合物和应用
EP2804630B1 (en) 2012-01-18 2017-10-18 F. Hoffmann-La Roche AG Methods of using fgf19 modulators
JP5343177B1 (ja) 2012-02-28 2013-11-13 アステラス製薬株式会社 含窒素芳香族へテロ環化合物
ES2916220T3 (es) 2012-07-11 2022-06-29 Blueprint Medicines Corp Inhibidores del receptor de factor de crecimiento de fibroblasto
AU2014228746B2 (en) 2013-03-15 2018-08-30 Celgene Car Llc Heteroaryl compounds and uses thereof
AU2014238443A1 (en) 2013-03-15 2015-07-30 Celgene Car Llc MK2 inhibitors and uses thereof
AU2014287209B2 (en) 2013-07-09 2019-01-24 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
AR097455A1 (es) 2013-08-28 2016-03-16 Astellas Pharma Inc Composición farmacéutica que contiene compuesto de pirimidina como un ingrediente activo
RU2715708C2 (ru) * 2013-10-18 2020-03-03 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Ингибиторы fgfr4
SMT202200292T1 (it) 2013-10-25 2022-09-14 Blueprint Medicines Corp Inibitori del recettore del fattore di crescita dei fibroblasti
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
SG10201810057UA (en) * 2015-04-14 2018-12-28 Eisai R&D Man Co Ltd Crystalline fgfr4 inhibitor compound and uses thereof
CN108884097B (zh) 2016-05-20 2021-05-28 浙江海正药业股份有限公司 嘧啶类衍生物、其制备方法和其在医药上的用途
WO2017198149A1 (zh) 2016-05-20 2017-11-23 江苏豪森药业集团有限公司 Fgfr4抑制剂、其制备方法和应用

Also Published As

Publication number Publication date
CN107660200B (zh) 2022-01-11
CA2982562A1 (en) 2016-10-20
KR20180003559A (ko) 2018-01-09
MX390378B (es) 2025-03-12
BR112017022243A2 (pt) 2018-07-10
US20200317645A1 (en) 2020-10-08
IL254974B (en) 2021-06-30
SG10201810057UA (en) 2018-12-28
SG11201708472WA (en) 2017-11-29
JP2021050231A (ja) 2021-04-01
JP2018188465A (ja) 2018-11-29
JP2018511635A (ja) 2018-04-26
WO2016168331A1 (en) 2016-10-20
AU2016248056B2 (en) 2020-07-23
EP3283465A1 (en) 2018-02-21
AU2020257131A1 (en) 2020-11-19
US20180093972A1 (en) 2018-04-05
CA2982562C (en) 2023-06-13
IL254974A0 (en) 2017-12-31
US11498916B2 (en) 2022-11-15
RU2763328C2 (ru) 2021-12-28
CN107660200A (zh) 2018-02-02
US10562888B2 (en) 2020-02-18
JP6431622B2 (ja) 2018-11-28
ES2864712T3 (es) 2021-10-14
KR102548229B1 (ko) 2023-06-27
EP3283465B1 (en) 2021-01-06
AU2016248056A1 (en) 2017-11-02
RU2017139246A (ru) 2019-05-14
RU2017139246A3 (es) 2019-10-22

Similar Documents

Publication Publication Date Title
MX2017013248A (es) Compuesto del inhibidor fgfr4 cristalino y usos del mismo.
CY2024024I1 (el) Υδροχλωρικα αλατα ν-(κυανομεθυλ)-4-(2-(4- μορφολινοφαινυλαμινο)πυριμιδιν-4-υλ)βενζαμιδιου
MA51619A (fr) Inhibiteurs de la protéine kinase dépendante de l'adn
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
MY192059A (en) Heterocyclic amides as kinase inhibitors
UY34161A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida, sus usos, y composiciones que la contienen
UY35998A (es) 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA
MX2019011789A (es) 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procesos para su preparacion.
HUE051693T2 (hu) 5-Klór-N4-[2-(dimetilfoszforil)-fenil]-N2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)-piperidin-1-il] -pirimidin-2,4-diamin kristályos formái
DK3658547T3 (da) Fremgangsmåde til fremstilling af n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamid
UY34191A (es) ?N-(6-((2R,3S)-3,4-Dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilazetidina-1-sulfonamida y sales farmacéuticamente aceptables de lamisma?.
TW201613888A (en) Crystalline forms of an NK-1 antagonist
ZA202003676B (en) Substituted thiophenyl uracils, salts thereof and the use thereof as herbicidal agents
EP3856174A4 (en) HDAC1, 2 INHIBITORS
MX2021000432A (es) Formas solidas de compuestos de 5,6-dihidro-6-fenilbenzo[f]isoquin olin-2-amina sustituidos.
UY37121A (es) Compuestos de N-(2-(fenil) piridina-4-il)-5-morfolinopiridina-3-sulfonamida como inhibidores de la actividad PL3-quinasa
EA201990320A1 (ru) Кристаллические формы 4-циано-n-(2-(4,4-диметилциклогекс-1-ен-1-ил)-6-(2,2,6,6-тетраметилтетрагидро-2h-пиран-4-ил)пиридин-3-ил)-1h-имидазол-2-карбоксамида
MX387254B (es) Proceso para la preparación de enantiómeros de pirlindol y sus sales.
MX2021010016A (es) Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfon il-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-m etilbenzoil)guanidina.
PL3898612T3 (pl) Podstawione pirydynyloksybenzeny, ich sole oraz zastosowanie jako aktywne składniki herbicydowe